“Dave Knapp is the person to follow to stay updated on all the latest obesity medication news including Eli Lilly and Novo Nordisk. He has been featured in Bloomberg and Yahoo Finance. As someone that has created a huge community for GLP-1 medications like Mounjaro/ZepBound/Ozempic/Wagovy, he knows the actual real-world experience of patients. He has been an excellent voice to their frustrations and triumphs.”
Clark a. Kent via Apple Podcasts ·
United States of America ·
04/19/24